Registry of Genetic Changes in Melanoma in Taiwan
Official title: T1622 The Registry Study of Genetic Alterations of Melanoma in Taiwan
Run by National Health Research Institutes, Taiwan · NCT06952400 · Data updated 2026-11-12
This study is trying to learn more about the genetic changes in different types of melanoma, especially those more common in Taiwan, to help improve treatment and outcomes for patients with this skin cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | National Health Research Institutes, Taiwan Academic / other |
| Drugs / interventions | immunotherapy, chemotherapy |
| Locations | 16 sites (Taipei, Taiwan/Taipei and 15 other locations) |
| Status | Recruiting |
| Started | August 22, 2022 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2030 |
| Registry record updated | May 6, 2025 |
| Trial ID | NCT06952400 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with pathologically confirmed melanoma at various stages, willing to provide tumor tissue samples.
✕Probably not a fit
Patients with non-melanoma skin cancers or those unable to provide tumor tissue samples may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather data on genetic alterations in various types of melanoma, particularly focusing on acral and mucosal melanoma, which are more prevalent in Taiwan compared to Caucasian populations. It will involve patients aged over 18 with pathologically confirmed melanoma, who will provide tumor tissue samples for analysis. The study seeks to understand the unique epidemiological and genetic features of melanoma in Taiwan to improve treatment strategies and patient outcomes. By comparing these findings with existing data from Western populations, the study aims to address the high recurrence rates and poor survival outcomes observed in Taiwanese melanoma patients.
Why it matters
Potential benefit: If successful, this study could lead to improved therapeutic strategies and better outcomes for melanoma patients in Taiwan.
How similar studies have gone: While there is limited data on similar studies specifically in Taiwan, research on genetic alterations in melanoma has shown promise in other populations, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \> 18 years old 2. Pathologically confirmed melanoma. (Patients with additional malignancies requiring treatment or follow-up are allowed. Only treatment for melanoma should be recorded). 3. ECOG performance status \< 3 4. Cohort 1(early acral melanoma): melanoma, stage I/II; Cohort 2 (locally advanced acral melanoma): melanoma, stage III, resectable; and Cohort 3 (advanced): unresectable / metastatic melanoma, stage III/IV or recurrent melanoma (unresectable). Staging is based on AJCC Cancer Staging System 8th edition). The patients with advanced melanoma with available comprehensive NGS report are included in cohort 4. 5. Willingness to provide archival or newly obtained tumor tissues for this study proposal 6. Life expectancy more than 3 months - 7. Patients fully understand the protocol with the willingness to have regular follow-up Exclusion Criteria: 1. Inability to cooperate by providing a complete medical history 2. No available tumor tissues for genetic testing (archived tissue sampling more than 5 years from screening date) 3. Undesirable compliance (Mental status is not fit for further treatment or data collection.)
Where it's running
-
Taipei Veterans General Hospital
Taipei, Taiwan/Taipei, Taiwan Recruiting -
CHANG GUNG MEMORIAL HOSPITAL, Chiayi
Chiayi City, Taiwan Recruiting -
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan Recruiting -
Kaohsiung Medical University
Kaohsiung City, Taiwan Recruiting -
National Taiwan University Hospital ,NTUH Hsin-Chu Branch
Sindian City, Taiwan Recruiting -
China Medical University Hospital
Taichung, Taiwan Recruiting
Show 10 more locations
-
Chung Shan Medical University Hospital
Taichung, Taiwan Recruiting -
Taichung Veterans General Hospital
Taichung, Taiwan Recruiting -
National Cheng Kung University Hospital
Tainan, Taiwan Recruiting -
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, Taiwan Recruiting -
MacKay Memorial Hospital
Taipei, Taiwan Recruiting -
National Taiwan University Hospital
Taipei, Taiwan Recruiting -
Taipei Medical University -Ministry of Health and Welfare Shuang-Ho Hospital
Taipei, Taiwan Recruiting -
Wan Fang Hospital, Taipei Medical University
Taipei, Taiwan Recruiting -
CHANG GUNG MEMORIAL HOSPITAL, Linkou
Taoyuan, Taiwan Recruiting -
Taoyuan General Hospital, Ministry of Health and Welfare
Taoyuan, Taiwan Recruiting
Study contacts
- Principal investigator: Chiao-En Wu, MD, PhD — Chang Gung Medical Foundation
- Study coordinator: Chien-Ya Hung, BS
- Email: 951106@nhri.edu.tw
- Phone: +886-3-7206166
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.